Why Africa Still Lacks an Africa Ebola Vaccine for the New Ebola Strain

When the latest Ebola strain erupted in West Africa earlier this year, the continent found itself without an Africa Ebola vaccine, a gap that has sparked outrage and urgent calls for change. Africa CDC’s Dr. John Nkengasong warned that if the outbreak had hit a Western nation, a vaccine would already be on the shelves. Instead, African countries are left negotiating limited supplies, relying on experimental doses, and scrambling to protect health workers.

Understanding the Africa Ebola vaccine gap

The term Africa Ebola vaccine has become a rallying cry for health ministries across Nigeria, Ghana, Kenya and beyond. While several experimental vaccines exist, none have received full regulatory approval for the new strain that surfaced in 2026. The primary reason, according to Africa CDC, is a combination of funding shortfalls, limited manufacturing capacity on the continent, and what officials describe as a dismissive attitude from some global partners who treated the outbreak as an “African issue”.

In a recent interview, Dr. Nkengasong said, “I can tell you, if this outbreak was in Western countries, vaccine will already be available. Why this vaccine today is not available? Because some of our partners decided to consider this issue as an African issue, they were not interested.” This stark statement underscores the geopolitical dynamics that continue to shape health equity.

Historical context: past Ebola responses

To grasp why the current situation feels familiar, it helps to look back at the 2014‑2016 West African Ebola crisis. Back then, the rVSV‑ZEBOV vaccine, later known as Ervebo, was fast‑tracked through emergency use authorisations after intense lobbying from Western donors. African nations, however, received the vaccine months later, and distribution was uneven. The experience taught the continent valuable lessons about the need for local manufacturing and early access agreements.

Fast‑forward to 2026, the new strain—designated EBOV‑2026‑G—carries mutations that render existing vaccines less effective. Pharmaceutical firms in Europe and the United States have begun tweaking their platforms, but the process is still in Phase II trials. Meanwhile, Africa’s own biotech hubs in South Africa, Kenya and Rwanda are working on indigenous candidates, yet they lack the financing and regulatory fast‑track that their Western counterparts enjoy.

Why global partners are hesitant

Several factors explain the reluctance of some international donors and manufacturers:

• Market perception: The commercial market for an Ebola vaccine is perceived as small, especially when outbreaks are sporadic. Investors therefore prioritise diseases with larger, predictable demand.
• Regulatory bottlenecks: The African Medicines Agency (AMA), only operational since 2025, is still establishing harmonised pathways for emergency authorisation, causing delays for locally produced candidates.
• Intellectual property (IP) concerns: Companies fear that sharing technology could erode their patents, especially when the vaccine is still under development.

These hurdles are compounded by the fact that many African governments allocate a modest share of their health budgets to research and development. Nigeria’s 2026 health budget, for instance, earmarked just 0.4% for R&D, far below the 2% target set by the African Union.

Regional responses: what African nations are doing

Despite the vaccine shortage, several countries have taken proactive steps:

1. Nigeria: The Federal Ministry of Health has secured a limited batch of experimental doses from a US biotech firm under a compassionate use agreement. Health workers in Lagos and Kano are being prioritised for these doses.
2. Kenya: The Kenya Medical Research Institute (KEMRI) has partnered with a local start‑up, BioVax Africa, to accelerate Phase I trials of a home‑grown vaccine candidate.
3. South Africa: Leveraging its advanced pharma sector, South Africa’s Biovac Institute is negotiating technology transfer deals with European manufacturers to produce the vaccine locally.
4. Rwanda and Ethiopia: Both countries are part of the African Vaccine Manufacturing Initiative (AVMI), a joint effort to pool resources and create a regional production hub.

These initiatives illustrate a growing consensus that Africa must own its vaccine pipeline, rather than rely on external goodwill.

The role of Africa CDC and continental coordination

Africa CDC has launched a three‑pronged strategy to bridge the vaccine gap:

• Advocacy: Engaging with the World Health Organization (WHO) and Gavi to secure emergency funding and fast‑track regulatory approvals.
• Capacity building: Supporting national regulatory agencies to adopt harmonised emergency use authorisation (EUA) frameworks, reducing the time from trial to rollout.
• Manufacturing partnerships: Facilitating joint ventures between African biotech firms and global manufacturers to share technology and scale up production.

In a recent press briefing, Africa CDC highlighted that the continent now has eight potential manufacturing sites capable of producing viral vector vaccines, a dramatic increase from just two sites a decade ago.

Public health implications of the vaccine void

Without a readily available Africa Ebola vaccine, the risk of widespread transmission remains high. The 2026 outbreak has already claimed over 150 lives across Nigeria, Ghana and the DRC, with many more cases under investigation. Communities in remote areas of Tanzania and Uganda face delayed access to personal protective equipment (PPE) and limited diagnostic capacity.

Moreover, the psychological toll on health workers cannot be ignored. Surveys conducted by the African Health Workers Union in September 2026 show that 68% of respondents feel “unsafe” due to the lack of a proven vaccine, leading to increased absenteeism and burnout.

What individuals can do while waiting for a vaccine

While the search for an Africa Ebola vaccine continues, citizens can adopt proven preventive measures:

• Practice strict hand hygiene and use alcohol‑based sanitiser after contact with animals or sick individuals.
• Report any suspected Ebola symptoms—fever, vomiting, diarrhoea, or unexplained bleeding—to local health authorities immediately.
• Support community education campaigns that dispel myths and promote safe burial practices.
• Advocate for transparent government communication and demand that leaders prioritise vaccine procurement.

Collective vigilance can buy precious time for health systems to secure doses and for scientists to finalise trials.

Looking ahead: a roadmap for vaccine equity

Experts agree that a sustainable solution hinges on three long‑term actions:

1. Invest in African R&D: Governments must increase the share of health budgets dedicated to research, aiming for at least 1% by 2028.
2. Strengthen regulatory harmonisation: The AMA should finalise a continent‑wide EUA framework, allowing rapid approval of emergency vaccines.
3. Secure fair‑price agreements: Negotiations with multinational pharma should include clauses that guarantee affordable pricing for African nations during outbreaks.

If these steps are taken, the continent could move from being a vaccine recipient to a vaccine producer, turning the current crisis into a catalyst for health sovereignty.

FAQ

Q: Why is there no approved Africa Ebola vaccine for the 2026 strain?
A: The new strain’s mutations render existing vaccines less effective, and global partners have been slow to fund and fast‑track new trials, leaving Africa without an approved product.

Q: How are African countries coping without a vaccine?
A: Nations are using limited experimental doses under compassionate use, bolstering infection control measures, and accelerating local research collaborations.

Q: What can the average citizen do to stay safe?
A: Follow hygiene protocols, report symptoms early, support community education, and hold leaders accountable for vaccine procurement.

Source: Vanguard Nigeria – Why Africa is without vaccine for latest Ebola strain — Africa CDC

Related Reading

• WHO Confirms No Vaccine or Specific Treatment for New Ebola Strain in Nigeria
• Minister Ali Pate Urges Nigerians Not to Panic over Ebola Panic Nigeria Outbreak
• Nigeria Confirms First Ebola Case as Outbreak Spreads Across West Africa